Related references
Note: Only part of the references are listed.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge et al.
HAEMATOLOGICA (2015)
Health-related quality of life in patients with multiple myeloma - does it matter?
Ann Kristin Kvam et al.
HAEMATOLOGICA (2015)
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
Laura C. Coates et al.
LANCET (2015)
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge et al.
HAEMATOLOGICA (2015)
Health-related quality of life in patients with multiple myeloma - does it matter?
Ann Kristin Kvam et al.
HAEMATOLOGICA (2015)
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
Meletios A. Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2014)
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Gareth J. Morgan et al.
CLINICAL CANCER RESEARCH (2013)
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial
Alaa M. Ali et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Gareth J. Morgan et al.
BLOOD (2012)
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
Gareth J. Morgan et al.
BLOOD (2012)
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
Michel Delforge et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J. Morgan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
Silvia G. R. Verelst et al.
ANNALS OF HEMATOLOGY (2011)
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J. Morgan et al.
BLOOD (2011)
Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
Kim Cocks et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
What changes in health-related quality of life matter to multiple myeloma patients? A prospective study
Ann K. Kvam et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K. Cocks et al.
EUROPEAN JOURNAL OF CANCER (2007)
Share Paper
